Dernières nouvelles pour Johnson & Johnson (NYSE:JNJ) Stock

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.

JOHNSON & JOHNSON ORD

RBC Capital analyst Shagun Singh maintains Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Outperform and raises the price target from $175 to $178.

News

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on Johnson & Johnson, Raises Price Target to $178

Monday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) said it discontinued the Phase 3 SunRISe-2 trial of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy for muscle-invasive urothelial carcinoma (MIBC) patients who are not receiving radical cystectomy.
Following an Independent Data Monitoring Committee <a target="_blank" href="https://www.jnj.com/media-center/press-releases/johnson-johnson-statement-on-the-sunrise-2-study" rel="noreferrer noopener">recommendation</a> and pre-specified interim analysis, <a target="_blank" href="https://clinicaltrials.gov/study/NCT04658862?term=SunRISe-2&amp;rank=1" rel="noreferrer noopener">SunRISe-2</a> was discontinued for not showing superiority versus chemoradiation.
&#8220;We remain confident in the TARIS platform having over $5 billion potential,&#8221; Johnson &amp; Johnson notes.
Data from the SunRISe-4 study recently&nbsp;<a target="_blank" href="https://www.jnj.com/media-center/press-releases/neoadjuvant-tar-200-plus-cetrelimab-nearly-doubles-the-pathological-complete-response-rate-compared-to-cetrelimab-alone-in-patients-with-muscle-invasive-bladder-cancer" rel="noreferrer noopener">presented</a> at the 2024 European Society for Medical Oncology Congress show the potential of TAR-200 in MIBC.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41189182/johnson-johnson-ends-phase-2-study-for-dengue-antiviral-amid-r-d-reprioritization" rel="noreferrer noopener">Johnson &amp; Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&amp;D Reprioritization</a>.
The company says it is on target for the FDA filing of TAR-200 monotherapy (SunRISe-1) in non-muscle invasive bladder cancer in early 2025, with the&nbsp;<a target="_blank" href="https://clinicaltrials.gov/ct2/show/NCT05714202?term=05714202&amp;draw=2&amp;rank=1" rel="noreferrer noopener">SunRISe-3</a> and&nbsp;<a target="_blank" href="https://clinicaltrials.gov/study/NCT06211764?term=sunrise-5&amp;rank=1" rel="noreferrer noopener">SunRISe-5</a> studies underway.
Johnson &amp; Johnson is set to release its third quarter 2024 earnings next Wednesday, 15 October. As per data from Benzinga Pro, the analysts estimate adjusted EPS of $2.20 and <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">revenue of $22.13 billion</a>.
Goldman Sachs has reiterated its Neutral rating while increasing the price target <a target="_blank" href="https://www.benzinga.com/quote/JNJ/analyst-ratings" rel="noreferrer noopener">from $155 to $162</a>.
The analyst expects the pharma giant to report third-quarter results in line with consensus expectations on the top line with revenues of $22.26 billion, with year-over-year growth of +4.4%, representing a slight incremental deceleration in the pace of growth from the first half of 2024.
Goldman Sachs&#8217; outlook for the quarter remains mostly consistent overall, with a slight upward revision to the Innovative Medicine forecast compared to estimates following the second-quarter results. This improvement is attributed to potentially less impact from introducing biosimilar Stelara in Europe during the third quarter.
This adjustment helps counterbalance a modest reduction in the MedTech segment forecasts.
&#8220;We expect management to reiterate guidance on the FY25 revenue growth outlook of +3% or more, and for longer-term targets (Innovative Medicine growth at a CAGR of 5-7% from 2025-30, and growth at the upper end of the 5-7% CAGR for MedTech from 2023-27) to remain intact,&#8221; the analyst writes.
Price Action: JNJ stock is down 0.21% at $159.20 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41234724/mercks-mumps-vaccine-controversy-class-action-lawsuit-alleges-anticompetitive-behavior-court-shie" target="_blank" rel="noreferrer noopener">Merck&#8217;s Mumps Vaccine Controversy: Class-Action Lawsuit Alleges Anticompetitive Behavior, Court Shields From Liability</a></li>
</ul>
Photo by Tada Images via Shutterstock

Analyst Color

Biotech

Earnings

Large Cap

Health Care

Trading Ideas

General

What To Expect When Johnson & Johnson Reports Q3 Earnings Next Week?

<a href="https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12108928?requestToken=eyJzdWIiOiI0N2NmZDc2OC05MjVlLTQzM2ItOGUyNi0xZjQyNDYxMDIyN2EiLCJ2ZXIiOiI1ZTZlZjY4OC1jYjkwLTQ1MWQtYWRmZS1kYTViYTA4MTRlY2UiLCJleHAiOjB9" title="https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12108928?requestToken=eyJzdWIiOiI0N2NmZDc2OC05MjVlLTQzM2ItOGUyNi0xZjQyNDYxMDIyN2EiLCJ2ZXIiOiI1ZTZlZjY4OC1jYjkwLTQ1MWQtYWRmZS1kYTViYTA4MTRlY2UiLCJleHAiOjB9">https://ppubs.uspto.gov/dirsearch-public/print/downloadBasicPdf/12108928?requestToken=eyJzdWIiOiI0N2NmZDc2OC05MjVlLTQzM2ItOGUyNi0xZjQyNDYxMDIyN2EiLCJ2ZXIiOiI1ZTZlZjY4OC1jYjkwLTQ1MWQtYWRmZS1kYTViYTA4MTRlY2UiLCJleHAiOjB9</a>

Verb Surgical Granted US Patent # 12,108,928 B2 For MACHINE-LEARNING-BASED VISUAL-HAPTIC SYSTEM FOR ROBOTIC SURGICAL PLATFORMS

Dean Omar Branham Shirley represents family of deceased woman
A Circuit Court in Cook County, Ill., has denied a request by Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) for a new trial in a mesothelioma lawsuit decided in April, upholding a jury verdict and award of $45 million in the asbestos-related death of a mother of six.
Johnson &amp; Johnson raised multiple issues in its motion for a new trial, but in each case, the court either found for the plaintiff or determined that any issue did not substantially prejudice the jury.
The decision from Judge Patrick J. Sherlock means the jury's verdict in the case filed by the children of Theresa Garcia will stand.

Legal

A Circuit Court In Cook County, Illinois Has Denied A Request By Johnson & Johnson For A New Trial In A Mesothelioma Lawsuit Decided In April; Upholding A Jury Verdict And Award Of $45M

On Friday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced discontinuing the Phase 2 field study evaluating the efficacy of investigational antiviral candidate mosnodenvir to prevent dengue virus in adults aged 18-65.
The <a target="_blank" href="https://www.jnj.com/media-center/press-releases/johnson-johnson-to-discontinue-phase-2-field-study-evaluating-investigational-antiviral-for-the-prevention-of-dengue" rel="noreferrer noopener">decision</a> to discontinue this study is part of a strategic reprioritization of the company&#8217;s Communicable Diseases research and development (R&amp;D) portfolio. No safety issues were identified.
Efficacy data from the Phase 2 field study will be available once the final data analyses, which are now underway, are complete.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41143856/johnson-johnsons-erleada-shows-improved-overall-survival-in-prostate-cancer-patients-compared-to-" rel="noreferrer noopener">Johnson &amp; Johnson&#8217;s Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer&#8217;s Drug</a>.
Mosnodenvir (formerly JNJ-1802) was shown to be safe and well tolerated in previous Phase 1 and Phase 2a clinical studies.
In October 2023, results from the Phase 2a human challenge study found that the compound induced antiviral activity against dengue (DENV-3) in humans, compared to placebo.
The study <a target="_blank" href="https://www.jnj.com/media-center/press-releases/janssen-announces-promising-antiviral-activity-against-dengue-in-a-phase-2a-human-challenge-model" rel="noreferrer noopener">evaluated</a> different dosing regimens – low, medium or high – of JNJ-1802 against an attenuated dengue 3 serotype (DENV-3) in healthy adults.
All participants received daily doses of JNJ-1802 or a placebo over 26 days, during which they were challenged with DENV-3 on day 5.
All participants were monitored over 85 days. The study found a dose-dependent antiviral effect on the detectability of DENV-3 RNA and time to first onset of detectable DENV-3 RNA compared to placebo and was safe and well-tolerated.
In May, Takeda Pharmaceutical Co Ltd&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) dengue vaccine&nbsp;received World Health Organization&#8217;s (WHO) prequalification.&nbsp;
TAK-003 is the second dengue vaccine to&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/04/31935884/united-nations-specialized-agency-in-preliminary-talks-with-takeda-for-dengue-vaccine-currently-u" rel="noreferrer noopener">be prequalified by WHO</a>.&nbsp;
WHO recommended using TAK-003 in children aged 6–16 in settings with high dengue burden <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38853309/takedas-dengue-vaccine-gets-who-approval-eligible-for-un-procurement" rel="noreferrer noopener">and transmission intensity</a>.&nbsp;
Price Action: JNJ stock is down 0.60% at $159.53 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41187920/lucid-air-electric-vehicles-join-blink-chargings-envoy-program-details" target="_blank" rel="noreferrer noopener">Lucid Air Electric Vehicles Join Blink Charging&#8217;s Envoy Program: Details</a>.</li>
</ul>
Photo via Shutterstock

Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization

Johnson & Johnson To Discontinue Phase 2 Field Study Evaluating Investigational Antiviral For Prevention Of Dengue; Decision To Discontinue Study Part Of A Strategic Reprioritization Of Company's Communicable Diseases R&D Portfolio; No Safety Issues Identified To Date In Phase 2 Field Study

Financial giants have made a conspicuous bearish move on Johnson &amp; Johnson. Our analysis of options history for Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) revealed 8 unusual trades.
Delving into the details, we found 25% of traders were bullish, while 75% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $294,749, and 4 were calls, valued at $638,264.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $155.0 and $162.5 for Johnson &amp; Johnson, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Johnson &amp; Johnson options trades today is 2676.43 with a total volume of 5,256.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Johnson &amp; Johnson's big money trades within a strike price range of $155.0 to $162.5 over the last 30 days.
<h3>Johnson &amp; Johnson Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727889417_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$2.61</td>
<td>$2.5</td>
<td>$2.52</td>
<td>$162.50</td>
<td>$504.0K</td>
<td>761</td>
<td>2.0K</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$1.23</td>
<td>$1.22</td>
<td>$1.23</td>
<td>$160.00</td>
<td>$128.4K</td>
<td>1.0K</td>
<td>380</td>
</tr>
<tr>
<td>JNJ</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/11/24</td>
<td>$1.29</td>
<td>$1.28</td>
<td>$1.28</td>
<td>$160.00</td>
<td>$103.8K</td>
<td>1.0K</td>
<td>2.2K</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/25/24</td>
<td>$2.92</td>
<td>$2.91</td>
<td>$2.92</td>
<td>$162.50</td>
<td>$55.7K</td>
<td>30</td>
<td>345</td>
</tr>
<tr>
<td>JNJ</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$11.0</td>
<td>$10.85</td>
<td>$10.85</td>
<td>$155.00</td>
<td>$45.5K</td>
<td>3.2K</td>
<td>95</td>
</tr>
</tbody>
</table>

<h3>About Johnson &amp; Johnson</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Having examined the options trading patterns of Johnson &amp; Johnson, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Current Position of Johnson &amp; Johnson</h3>
<ul>
<li>Trading volume stands at 2,469,466, with JNJ's price down by -0.48%, positioned at $161.21.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 13 days.</li>
</ul>
<h3>What The Experts Say On Johnson &amp; Johnson</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $207.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $175. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $215. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $215. 
&#x2A; In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $215. 
&#x2A; Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $215.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Johnson &amp; Johnson options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Johnson & Johnson's Options: A Look at What the Big Money is Thinking

Wednesday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) revealed results from a head-to-head study of Erleada (apalutamide) compared to Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Xtandi (enzalutamide).
The data showed that Erleada (apalutamide) provided a statistically significant overall survival benefit at 24 months compared to enzalutamide in patients with metastatic castration-<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41140779/erleada-apalutamide-demonstrates-statistically-significant-and-clinically-meaningful-improvement-i" rel="noreferrer noopener">sensitive prostate cancer (mCSPC)</a>.
Presented at the 6th European Congress of Oncology Pharmacy, the study of nearly 4,000 patients represents the largest real-world, head-to-head analysis of these two androgen receptor pathway inhibitors (ARPIs) in mCSPC.
The analysis demonstrated patients with mCSPC who initiated Erleada as their first ARPI had a statistically significant 23% reduction in their risk of death at 24 months compared to patients who initiated enzalutamide.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/41140319" rel="noreferrer noopener">Humana Faces Sharp Decline In Medicare Star Ratings For 2025, Braces For 2026 Revenue Hit</a>
The proportion of patients alive at 24 months (87.6%) observed in the Erleada cohort in this real-world analysis is consistent with that in the Phase 3 TITAN trial (82.4%).
TITAN demonstrated a statistically significant superior overall survival benefit of Erleada plus androgen deprivation therapy (ADT) compared to ADT alone at the primary analysis after a median of 22.7 months of follow-up and at the final analysis after a median of 44 months of follow-up.
On Tuesday, Johnson &amp; Johnson&nbsp;<a target="_blank" href="https://www.jnj.com/media-center/press-releases/johnson-johnson-to-invest-more-than-2-billion-in-new-advanced-technology-manufacturing-facility-in-north-carolina-to-support-robust-portfolio-growth" rel="noreferrer noopener">announced</a> an investment of more than $2 billion to build a biologics manufacturing facility in Wilson, North Carolina.
The new facility will expand the production of the company&#8217;s portfolio and pipeline of biologics in support of&nbsp;its broader plan to advance more than 70 novel therapies and product expansion filings and launches by the end of the decade.
When fully operational, the site will employ approximately 420 full-time employees.
Construction is anticipated to begin in the first half of 2025.
Price Action: JNJ stock is down 0.26% at $161.58 at last check Wednesday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41141541/whats-going-on-with-chinese-stocks-alibaba-nio-xpeng-li-auto-on-wednesday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Chinese Stocks Alibaba, NIO, XPeng, Li Auto On Wednesday?</a></li>
</ul>

Equities

Johnson & Johnson's Erleada Shows Improved Overall Survival In Prostate Cancer Patients Compared To Pfizer's Drug

Largest head-to-head real-world study in mCSPC demonstrated that ERLEADA&#xAE; reduced risk of death by 23 percent at 24 months compared to enzalutamide
LISBON, Portugal, Oct. 2, 2024 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced the results of a landmark real-world, head-to-head study showing that ERLEADA&#xAE; (apalutamide) provided a statistically significant overall survival benefit at 24 months compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC). Presented at the 6th European Congress of Oncology Pharmacy (ECOP) in Lisbon, Portugal, on October 2 (<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4268936-1&amp;h=3004083318&amp;u=https%3A%2F%2Fecop.events%2Fwp-content%2Fuploads%2F2024%2F09%2FClinical_evaluation.pdf&amp;a=Abstract+%23P31">Abstract #P31</a>), this study of nearly 4,000 patients represents the largest real-world, head-to-head analysis of these two androgen receptor pathway inhibitors (ARPIs) in mCSPC.
The study applied U.S. Food and Drug Administration (FDA) real-world evidence guidance and employed robust methodology, data sources and a large, diverse cohort to ensure validity of its findings. The retrospective study identified mCSPC patients who initiated ERLEADA&#xAE; or enzalutamide between December 16, 2018 – December 31, 2023, based on patient data in electronic databases. There were 1,800 ERLEADA&#xAE; and 1,909 enzalutamide initiators who met study criteria.
The analysis demonstrated patients with mCSPC who initiated ERLEADA&#xAE; as their first ARPI had a statistically significant 23 percent reduction in their risk of death at 24 months compared to patients who initiated on enzalutamide (hazard ratio [HR], 0.77; 95% confidence interval [CI], 0.62-0.96;&nbsp;P&lt;0.019). The proportion of patients alive at 24 months (87.6 percent) observed in the ERLEADA&#xAE; cohort in this real-world analysis is consistent with that in the Phase 3 TITAN trial (82.4 percent).1 TITAN demonstrated a statistically significant superior overall survival benefit of ERLEADA&#xAE; plus androgen deprivation therapy (ADT) compared to ADT alone at the primary analysis after a median 22.7 months of follow-up (HR 0.67; 95% CI, 0.51-0.89;&nbsp;P=0.005) and at the final analysis after a median 44 months of follow-up (HR 0.65; 95% CI, 0.53-0.79;&nbsp;P&lt;0.0001).1,2

Johnson & Johnson Presents Results From Study Showing That ERLEADA Demonstrates Statistically Significant And Clinically Meaningful Improvement In Overall Survival Compared To Enzalutamide In Patients With Metastatic Castration-sensitive Prostate Cancer

Johnson & Johnson To Invest More Than $2B In New, Advanced Technology Manufacturing Facility In North Carolina To Support Robust Portfolio Growth

Results from CEPHEUS study highlight DARZALEX FASPRO&#xAE; quadruplet regimen as a potential standard of care in newly diagnosed patients regardless of transplant eligibility
New indication would be the first FDA-approved treatment regimen for newly diagnosed multiple myeloma based on a study with MRD-negativity as the primary endpoint
RARITAN, N.J., Sept. 30, 2024 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for DARZALEX&nbsp;FASPRO&#xAE; (daratumumab and hyaluronidase-fihj) in combination with bortezomib, lenalidomide and dexamethasone (D-VRd) for the treatment of adult patients with newly diagnosed multiple myeloma (NDMM) for whom autologous stem cell transplant (ASCT) is deferred or who are ineligible for ASCT. &nbsp;

Johnson & Johnson Files For U.S. FDA Approval Of Darzalex Faspro-Based Quadruplet Regimen For Newly Diagnosed Multiple Myeloma Patients For Whom Transplant Is Not Planned

Friday, Legend Biotech Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>) and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)&nbsp;announced late-breaking three-year follow-up data from the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41075653/carvykti-is-the-first-and-only-cell-therapy-to-significantly-extend-overall-survival-compared-to-s" rel="noreferrer noopener">Phase 3 CARTITUDE-4 study.</a>
Data shows that a single infusion of Carvykti&nbsp;(ciltacabtagene autoleucel) significantly extended overall survival (OS) for relapsed or lenalidomide-refractory multiple myeloma patients who have received at least one <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/g41075653/carvykti-is-the-first-and-only-cell-therapy-to-significantly-extend-overall-survival-compared-to-s" rel="noreferrer noopener">prior line of therapy</a>.
The company says Carvykti&nbsp;is now the first and only cell therapy to improve OS versus standard therapies for patients with lenalidomide-refractory multiple myeloma as early as the second line.
These results were presented at the 2024 International Myeloma Society Annual Meeting.
The Phase 3 CARTITUDE-4 study evaluated Carvykti&nbsp;compared to standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone&nbsp;(DPd) for relapsed or lenalidomide-refractory multiple myeloma after one prior line of therapy.
<ul>
<li>At a median follow-up of almost three years (34 months), median OS was not reached for patients in the Carvykti&nbsp;arm.</li>
<li>At 30-month follow-up, OS rates were 76% in the Carvykti&nbsp;arm and 64% for patients treated with standard therapies.&nbsp;</li>
</ul>
In patients randomized to the Carvykti arm, Carvykti reduced the risk of death by 45% compared to standard therapies, demonstrating clinically meaningful responses for patients as early as after the first relapse.
<ul>
<li>Median progression-free survival (PFS) was not reached in the Carvykti arm and 11.79 months in patients treated with standard therapies, demonstrating sustained deep and durable responses.</li>
<li>Patients in the Carvykti&nbsp;arm had a 77% complete response or better and an 85% overall response rate.</li>
<li>Patients in the Carvykti&nbsp;arm had 62% minimal residual disease (MRD)negativity at 10-5&nbsp;and 57% MRD negativity at 10-6, compared to patients treated with standard therapies (18.5%, 9%), respectively.</li>
<li>The Median duration of response was not reached in the Carvykti&nbsp;arm, but it was 18.69 months for patients treated with standard therapies.</li>
<li>Median time to symptom worsening was not reached with Carvykti&nbsp;and 34.33 months with patients treated with standard therapies.</li>
</ul>
William Blair views this data as a positive step for the company, reinforcing the case for Carvykti&#8217;s use in second-line treatment.
The analyst writes that the near-term revenue and stock performance will largely depend on the availability of commercial manufacturing slots. William Blair&#8217;s outlook remains that Legend&#8217;s valuation fairly reflects the approval of Carvykti in second-line-plus treatment, its anticipated peak revenue, and the current progress of its other pipeline programs.
Price Action: LEGN stock is up 2.29% at $50.40 during the premarket session at last check Monday.
Illustration of Phrama lab worker created with MidJourney
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41091774/prime-medicine-inks-cell-therapy-pact-with-bristol-myers-squibb-worth-over-3-5b-streamlines-pipel" target="_blank" rel="noreferrer noopener">Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline</a>.</li>
</ul>

Movers

LEGN

Johnson & Johnson/ Legend Biotech Partnered Blood Cancer Drug Extends Overall Survival, Support Use In Previously Treated Patients

Cantor Fitzgerald analyst Louise Chen reiterates Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) with a Overweight and maintains $215 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Johnson & Johnson, Maintains $215 Price Target

Johnson & Johnson Launches TECNIS Odyssey Intraocular Lens In U.S., Offering Cataract Patients Precise Vision At All Distances And Improved Contrast In Low Light, With 93% Achieving Glasses-Free Vision

45 percent reduction in risk of death achieved with CARVYKTI&reg; after three-year follow-up in landmark CARTITUDE-4 study&nbsp;
Data featured in a late-breaking oral presentation at the 2024 International Myeloma Society Annual Meeting
RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today long-term results from the Phase 3 CARTITUDE-4 study that show a single infusion of CARVYKTI&reg; (ciltacabtagene autoleucel)&nbsp;significantly extended overall survival (OS) in patients with relapsed or lenalidomide-refractory multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor (PI), reducing the risk of death by 45 percent versus standard therapies of pomalidomide, bortezomib and dexamethasone (PVd) or daratumumab, pomalidomide and dexamethasone (DPd).1 With these data, CARVYKTI&reg; is now the first and only cell therapy to improve OS versus standard therapies for patients with lenalidomide-refractory multiple myeloma as early as second line.1&nbsp;Findings were featured as a late-breaking oral presentation at the 2024 International Myeloma Society (IMS) Annual Meeting (Abstract #OA-65).1

Johnson & Johnson And  Legend Biotech Corp Announce CARVYKTI Is The First And Only Cell Therapy To Significantly Extend Overall Survival Versus Standard Therapies For Patients With Multiple Myeloma As Early As Second Line; 45% Reduction In Risk Of Death Achieved With CARVYKTI After Three-year Follow-up In Landmark CARTITUDE-4 Study

On Friday, Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) released updated results from the investigational Phase&nbsp;1b&nbsp;RedirecTT-1 study evaluating the combination of Talvey&nbsp;(talquetamab) and Tecvayli&nbsp;(teclistamab) in patients with relapsed or <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n41065095/novel-combination-of-talvey-talquetamab-tgvs-and-tecvayli-teclistamab-cqyv-suggests-high-response-" rel="noreferrer noopener">refractory multiple myeloma</a>.
At data cutoff, 44 patients had been treated with the recommended phase 2 regimen (RP2R) of 0.8 mg/kg of Talvey in combination with 3 mg/kg of Tecvayli every other week.
The overall response rate (ORR) was 79.5%, with a complete response or better (CR+) rate of 52.3%, an 18-month duration of response (DOR) of 85.9%, and an 18-month progression-free survival (PFS) rate of 69.8% with a median follow-up of 18.2 months.
Results from a subgroup analysis of patients with extramedullary disease demonstrated an ORR of 61.1%, with a CR+ rate of 33.3%, an 18-month DOR of 81.8%, and an 18-month PFS rate of 52.9% in patients with EMD at median follow-up 13.6 months.
Johnson &amp; Johnson&nbsp;also revealed updated results from the investigational Phase&nbsp;1b&nbsp;TRIMM-2 study evaluating the combination of Talvey with Darzalex&nbsp;Faspro and pomalidomide in patients with relapsed or refractory multiple myeloma that demonstrated <a target="_blank" href="https://www.benzinga.com/pressreleases/24/09/n41064961/talvey-talquetamab-tgvs-and-darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-combination-s" rel="noreferrer noopener">an ORR of 82%</a>.
At data cutoff, 77 patients had received Talvey&nbsp;in doses of 0.4 mg/kg weekly (QW) or 0.8 mg/kg biweekly (Q2W),&nbsp;with step-up doses&nbsp;combined with Darzalex&nbsp;Faspro and pomalidomide.
In the QW arm (n=18), the overall response rate (ORR) was 100%, with 56 percent having a complete response (CR) or better.
The Q2W arm (n=59) achieved 76% ORR, with 56% achieving CR or better.
The median duration of response (DOR) in the Q2W arm was 26.4 months, and the median progression-free survival (PFS) was 20.3 months.
Results showed that 52% of anti-CD38 refractory patients (n=64) achieved CR or better, and 70.8% received prior chimeric antigen receptor T cell therapy (n=24) achieved CR or better.
Patients who had received prior bispecific antibodies (n=29) achieved an 82.8% ORR.
Price Action: JNJ stock is trading 0.83% higher at $162.73 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/09/41066968/microsoft-google-meta-pave-path-to-ai-expansion-nvidia-and-broadcom-set-to-reap-benefits" target="_blank" rel="noreferrer noopener">Microsoft, Google, Meta Pave Path to AI Expansion, Nvidia and Broadcom Set to Reap Benefits</a>.</li>
</ul>
Photo via Shutterstock

Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment

Data from the investigational Phase 1b RedirecTT-1 study demonstrate a safety profile consistent to TALVEY&#xAE; and TECVAYLI&#xAE; monotherapies
RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced updated results from the investigational Phase 1b RedirecTT-1 study evaluating the first-ever bispecific antibody combination of TALVEY&#xAE; (talquetamab-tgvs), the first and only FDA-approved bispecific targeting GPRC5D, and TECVAYLI&#xAE; (teclistamab-cqyv), the first FDA-approved BCMA-directed bispecific therapy, showing high response rates and durable responses, with a consistent safety profile to each monotherapy, in patients with relapsed or refractory multiple myeloma (RRMM) who were triple-class exposed, including those with extramedullary disease. These data were featured in an oral presentation at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4264836-1&amp;h=917760301&amp;u=https%3A%2F%2Fevents.jspargo.com%2Fims24%2FPublic%2FEnter.aspx&amp;a=2024+International+Myeloma+Society+Annual+Meeting">2024 International Myeloma Society Annual Meeting</a>&nbsp;(Abstract # OA – 03).

Johnson & Johnson Announced Updated Results From The Investigational Phase 1b RedirecTT-1 Study Evaluating The First-ever Bispecific Antibody Combination Of  TALVEY And TECVAYLI Suggests High Response Rates And Durable Responses In Triple-Class Refractory Patients With Relapsed Or Refractory Multiple Myeloma, Including Those With Extramedullary Disease

Updated data show 100 percent overall response rate with 56 percent of patients achieving complete response or better with weekly dosing, supporting the combinability of the GPRC5D bispecific antibody
Safety profile, including infection rates, similar to TALVEY&#xAE; and DARZALEX FASPRO&#xAE; monotherapies
RIO DE JANEIRO, Sept. 27, 2024 /PRNewswire/ --&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) today announced updated results from the investigational Phase 1b TRIMM-2 study evaluating the combination of TALVEY&#xAE; (talquetamab-tgvs) with DARZALEX FASPRO&#xAE;&nbsp;(daratumumab and hyaluronidase-fihj) and pomalidomide in patients with relapsed or refractory multiple myeloma that demonstrated an overall response rate (ORR) of 82 percent, further supporting the investigation of this combination. These data were featured in an oral presentation at the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4264815-1&amp;h=1131024819&amp;u=https%3A%2F%2Fevents.jspargo.com%2Fims24%2FPublic%2FEnter.aspx&amp;a=2024+International+Myeloma+Society+Annual+Meeting">2024 International Myeloma Society Annual Meeting</a>&nbsp;(Abstract #OA – 01).
The results from the Phase 1b TRIMM-2 study evaluating TALVEY&#xAE;, the first bispecific T-cell engager to target GPRC5D, combined with DARZALEX FASPRO&#xAE;, the first subcutaneous anti-CD38 monoclonal antibody, and pomalidomide included patients who received at least three prior lines of therapy, including a proteasome inhibitor (PI) and immunomodulatory drug (IMiD), or were double refractory to a PI and IMiD and had not received anti-CD38 therapy in the previous 90 days.1&nbsp;
At data cutoff, 77 patients had received TALVEY&#xAE; in doses of 0.4 mg/kg weekly (QW) or 0.8 mg/kg biweekly (Q2W),&nbsp;with step-up doses,&nbsp;combined with DARZALEX FASPRO&#xAE; and pomalidomide. In the QW arm (n=18), the overall response rate (ORR) was 100 percent, with 56 percent having a complete response (CR) or better. The Q2W arm (n=59) achieved 76 percent ORR, with 56 percent achieving CR or better. The median duration of response (DOR) in the Q2W arm was 26.4 months, and the median progression-free survival (PFS) was 20.3 months. Results showed 52 percent of patients who are anti-CD38 refractory (n=64) achieved CR or better and 70.8 percent of patients who received prior chimeric antigen receptor T cell (CAR-T) therapy (n=24) achieved CR or better. Patients who had received prior bispecific antibodies (n=29) achieved an 82.8 percent ORR.1&nbsp;

Johnson & Johnson Announces Updated Results From The Investigational Phase 1b Trimm-2 Study Evaluating The Combination Of TALVEY And DARZALEX FASPRO Based Combination Shows Deep And Durable Responses In Patients With Relapsed Or Refractory Multiple Myeloma

In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article, we will undertake an in-depth industry comparison, assessing Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) alongside its primary competitors in the Pharmaceuticals industry. By meticulously examining crucial financial indicators, market positioning, and growth potential, we aim to provide valuable insights to investors and shed light on company's performance within the industry.
<h3>Johnson &amp; Johnson Background</h3>
Johnson &amp; Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
<table>
<thead>
<tr>
<th>Company</th>
<th>P/E</th>
<th>P/B</th>
<th>P/S</th>
<th>ROE</th>
<th>EBITDA (in billions)</th>
<th>Gross Profit (in billions)</th>
<th>Revenue Growth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johnson &amp; Johnson</td>
<td>24.30</td>
<td>5.40</td>
<td>4.56</td>
<td>6.62%</td>
<td>$7.8</td>
<td>$15.58</td>
<td>4.31%</td>
</tr>
<tr>
<td>Eli Lilly and Co</td>
<td>113.86</td>
<td>61.38</td>
<td>21.47</td>
<td>22.5%</td>
<td>$4.12</td>
<td>$9.13</td>
<td>35.98%</td>
</tr>
<tr>
<td>Novo Nordisk AS</td>
<td>42.44</td>
<td>33.71</td>
<td>14.79</td>
<td>18.97%</td>
<td>$35.74</td>
<td>$57.79</td>
<td>25.34%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc</td>
<td>21.25</td>
<td>6.67</td>
<td>4.68</td>
<td>13.0%</td>
<td>$7.45</td>
<td>$12.37</td>
<td>7.16%</td>
</tr>
<tr>
<td>AstraZeneca PLC</td>
<td>37.64</td>
<td>6.08</td>
<td>4.93</td>
<td>5.01%</td>
<td>$4.12</td>
<td>$10.76</td>
<td>13.33%</td>
</tr>
<tr>
<td>Novartis AG</td>
<td>23.81</td>
<td>5.65</td>
<td>4.92</td>
<td>7.97%</td>
<td>$5.25</td>
<td>$9.7</td>
<td>9.6%</td>
</tr>
<tr>
<td>Sanofi SA</td>
<td>30.35</td>
<td>1.76</td>
<td>2.70</td>
<td>1.53%</td>
<td>$2.03</td>
<td>$7.97</td>
<td>6.53%</td>
</tr>
<tr>
<td>Zoetis Inc</td>
<td>37.55</td>
<td>17.47</td>
<td>9.86</td>
<td>12.45%</td>
<td>$0.97</td>
<td>$1.69</td>
<td>8.3%</td>
</tr>
<tr>
<td>GSK PLC</td>
<td>13.46</td>
<td>4.31</td>
<td>1.75</td>
<td>8.32%</td>
<td>$2.31</td>
<td>$5.76</td>
<td>9.84%</td>
</tr>
<tr>
<td>Takeda Pharmaceutical Co Ltd</td>
<td>44.56</td>
<td>0.85</td>
<td>1.51</td>
<td>1.26%</td>
<td>$388.51</td>
<td>$821.04</td>
<td>14.11%</td>
</tr>
<tr>
<td>Dr Reddy's Laboratories Ltd</td>
<td>19.94</td>
<td>3.76</td>
<td>3.84</td>
<td>4.84%</td>
<td>$21.72</td>
<td>$46.34</td>
<td>13.87%</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals PLC</td>
<td>18.28</td>
<td>1.77</td>
<td>1.93</td>
<td>4.52%</td>
<td>$0.36</td>
<td>$0.91</td>
<td>6.95%</td>
</tr>
<tr>
<td>Organon &amp; Co</td>
<td>4.90</td>
<td>34.03</td>
<td>0.77</td>
<td>203.12%</td>
<td>$0.43</td>
<td>$0.94</td>
<td>-0.06%</td>
</tr>
<tr>
<td>Corcept Therapeutics Inc</td>
<td>37.65</td>
<td>7.46</td>
<td>8.27</td>
<td>6.14%</td>
<td>$0.04</td>
<td>$0.16</td>
<td>39.15%</td>
</tr>
<tr>
<td>Prestige Consumer Healthcare Inc</td>
<td>17.31</td>
<td>2.09</td>
<td>3.19</td>
<td>2.94%</td>
<td>$0.08</td>
<td>$0.15</td>
<td>-4.36%</td>
</tr>
<tr>
<td>Average</td>
<td>33.07</td>
<td>13.36</td>
<td>6.04</td>
<td>22.33%</td>
<td>$33.8</td>
<td>$70.34</td>
<td>13.27%</td>
</tr>
</tbody>
</table>
<style>
 table {
 width: 100%;
 border-collapse: collapse;
 font-family: Arial, sans-serif;
 font-size: 14px;
 }

 th, td {
 padding: 8px;
 text-align: left;
 }

 th {
 background-color: #293a5a;
 color: #fff;
 text-align: left;
 }

 tr:nth-child(even) {
 background-color: #f2f4f8;
 }

 tr:hover {
 background-color: #e1e4ea;
 }

 td:nth-child(3), td:nth-child(5) {
 text-align: left;
 }

 .dividend-amount {
 font-weight: bold;
 color: #0d6efd;
 }

 .dividend-frequency {
 font-size: 12px;
 color: #6c757d;
 }
 </style>Upon a comprehensive analysis of Johnson &amp; Johnson, the following trends can be discerned: 
<ul>
<li>
With a Price to Earnings ratio of 24.3, which is 0.73x less than the industry average, the stock shows potential for growth at a reasonable price, making it an interesting consideration for market participants.
</li>
<li>
With a Price to Book ratio of 5.4, significantly falling below the industry average by 0.4x, it suggests undervaluation and the possibility of untapped growth prospects.
</li>
<li>
The Price to Sales ratio is 4.56, which is 0.75x the industry average. This suggests a possible undervaluation based on sales performance.
</li>
<li>
With a Return on Equity (ROE) of 6.62% that is 15.71% below the industry average, it appears that the company exhibits potential inefficiency in utilizing equity to generate profits.
</li>
<li>
The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $7.8 Billion is 0.23x below the industry average, suggesting potential lower profitability or financial challenges.
</li>
<li>
The gross profit of $15.58 Billion is 0.22x below that of its industry, suggesting potential lower revenue after accounting for production costs.
</li>
<li>
The company's revenue growth of 4.31% is significantly lower compared to the industry average of 13.27%. This indicates a potential fall in the company's sales performance.
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1727362846_0.png" alt="debt to equity" />
The debt-to-equity (D/E) ratio provides insights into the proportion of debt a company has in relation to its equity and asset value.
Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.
When evaluating Johnson &amp; Johnson alongside its top 4 peers in terms of the Debt-to-Equity ratio, the following insights arise:
<ul>
<li>
Johnson &amp; Johnson has a stronger financial position compared to its top 4 peers, as evidenced by its lower debt-to-equity ratio of 0.58.
</li>
<li>
This suggests that the company has a more favorable balance between debt and equity, which can be perceived as a positive indicator by investors.
</li>
</ul>
<h3>Key Takeaways</h3>
For Johnson &amp; Johnson in the Pharmaceuticals industry, the PE, PB, and PS ratios are all low compared to its peers, indicating potential undervaluation. However, the low ROE, EBITDA, gross profit, and revenue growth suggest underperformance relative to industry standards. This may require further investigation into the company's operational efficiency and growth strategies to align with industry peers.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Analysis: Johnson &amp; Johnson Versus Competitors In Pharmaceuticals Industry

In October 2023, Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced its plans to spin off its consumer healthcare business as the French pharmaceutical company outlined its strategic update to increase investment in its drug-development <a target="_blank" href="https://www.benzinga.com/general/biotech/23/10/35458838/sanofi-goes-the-rival-way-plans-separation-of-consumer-healthcare-unit" rel="noreferrer noopener">pipeline and cut costs</a>.
Sanofi said the spinoff would allow it to increase its focus on innovative medicines and vaccines.
Sanofi&#8217;s consumer health unit boasts a portfolio that includes popular over-the-counter products like Phytoxil cough syrups, Icy Hot pain relief gels, and Dulcolax laxative tablets.&nbsp;
According to a Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-09-24/sanofi-said-to-get-binding-bids-from-cd-r-pai-for-consumer-arm?srnd=prognosis&amp;embedded-checkout=true" rel="noreferrer noopener">report</a>, two private equity firms, Clayton Dubilier &amp; Rice and PAI Partners, made separate bids for Sanofi&#8217;s consumer health division.
The update pushes the European pharma giant closer to one of the largest European deals this year, which could value the unit at 15 billion euros ($16.8 billion) or more, the Bloomberg report added.
The separation is expected to occur by Q4 2024 by creating a publicly listed entity headquartered in France.
In July, Goldman Sachs Group Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) and&nbsp;Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) said they were preparing to arrange more than $6.5 billion (6 billion euros) in debt financing for potential buyers interested in acquiring&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39755459/sanofis-20b-consumer-health-unit-sale-goldman-sachs-morgan-stanley-line-up-6-5b-financing" rel="noreferrer noopener">Sanofi&#8217;s&nbsp;consumer health division</a>.
The move highlighted banks&#8217; interest in supporting leveraged buyouts through pre-arranged financing.
Sanofi may opt for a spinoff of its consumer health business if the offers aren&#8217;t appealing, Bloomberg noted, citing sources. A company spokesperson told Bloomberg that Sanofi is evaluating potential separation options, with the earliest possible transaction happening in the fourth quarter of this year, and noted that preparations are progressing as planned.
In November 2023, Sanofi reportedly initiated talks with Rothschild &amp; Co. to explore the possibility of spinning off its consumer health division, which could potentially value the business <a target="_blank" href="https://www.benzinga.com/markets/equities/23/11/35823034/major-buyout-firms-eye-sanofis-consumer-health-division-spinoff-valued-over-20b" rel="noreferrer noopener">at over $20 billion</a>.&nbsp;
Rival pharma giants&nbsp;GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>)&nbsp;and&nbsp;Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) split their consumer healthcare units&nbsp;Haleon Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>) and Kenvue Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVUE#NYSE">KVUE</a>), respectively.
Price Action: SNY stock closed at $57.62&nbsp;on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/09/41012667/healthcare-software-giant-epic-systems-hit-with-lawsuit-over-alleged-monopolistic-practices" target="_blank" rel="noreferrer noopener">Healthcare Software Giant Epic Systems Hit With Lawsuit Over Alleged Monopolistic Practices</a>.</li>
</ul>
Photo via Company

Rumors

Media

KVUE

Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff

Stock Picks From Seeking Alpha's September 2024 New Analysts

Johnson & Johnson halts mid-stage study for dengue antiviral

Election Outcome Presents Opportunity For Investors

Buy 2 October Dogs Of The Dow And Watch 5 More

5 Relatively Secure And Cheap Dividend Stocks To Invest In -- October 2024

EDOW: Dow Industrials ETF Puts Dent In 'Buy And Hold' Myth

J&J discontinues Phase 2 study for bladder cancer drug TAR-200

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Chris Shibutani fro...

Johnson & Johnson: Hold Rating Affirmed Amid Balanced Growth and Caution

Undervalued Dividend Kings: October 2024

Harris home health care benefit likely funded through Medicare drug negotiations savings

ABBV

ACTV

AFMC

AFSM

AMGN

AMZN

ARCC

ARKK

AVUV

BAPR

BAYZF

CBSH

CINF

CRWD

CSCO

CTAS

CUKPF

EDOW

EVGGF

EVVTY

FANG

FROG

FSLR

GLPI

GOOG

GOOGL

GRAL

ICLN

INMD

INTC

IVOO

IVOV

LANC

LRCX

MAGS

MDALF

MNESP

MPLX

MSEX

MSEXP

MSFT

NDSN

NVDA

ODFL

OLPX

PILBF

QCOM

REGN

RIOCF

SOUN

SOUNW

SPGI

SPLV

SPMD

SPMO

SPMV

SPSM

SPUS

SPUU

SPVM

SPVU

SPXE

SPXL

SPXN

SPXS

SPXT

SPXU

SPXV

SPYD

SPYG

SPYV

SPYX

SQEW

SQLV

SSPY

SVAL

SYLD

TDBCP

TDBKF

TDOMF

TDOPF

TMDV

TNTTF

TPHD

TPLC

TPSC

TROLB

TSLA

UAUG

UBSI

UJAN

UMAR

UMAY

UOCT

UPRO

USMC

USMF

USVM

VOYA

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-04-30 at 5.36.02 PM

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

MRNA

3 Trends In Healthcare Guided By AI And The Companies Behind The Innovation

Screenshot 2024-03-13 at 5.45.52 PM

FDXTF

SHTDY

Nanotechnology&#39;s Promising Role In Fighting Infectious Diseases: Protecting Surfaces With FendX&#39;s Nanotechnology

Press Releases

Novel combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease

DARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned

DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma

CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line

Johnson & Johnson Rolls Out New TECNIS Odyssey Next-Generation Intraocular Lens Offering Cataract Patients Precise Vision at Every Distance in Any Lighting

Johnson & Johnson files for U.S. FDA approval of DARZALEX FASPRO®-based quadruplet regimen for newly diagnosed multiple myeloma patients for whom transplant is not planned

ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer

Small Cap

Opinion

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More

Chicago Court Upholds $45 Million Mesothelioma Verdict Against Johnson & Johnson

Johnson & Johnson to Participate in the Guggenheim Global Healthcare Conference

ANVS

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Comments

Johnson & Johnson

Actualités

Dernières nouvelles pour Johnson & Johnson (NYSE:JNJ) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL